Search

Adults with myelomeningocoele: life situation and bladder and bowel management

Long-term outcome studies of patients to include what happens at transition to adulthood are rare but increasing in the literature as paediatric urologists are questioning their long-term results more deeply. These authors aimed to assess life situation and bladder and...

Non-urothelial tumours of bladder – impact on oncological outcomes

Non-urothelial bladder tumours are not very common and they are generally considered to be high risk tumours when compared to standard urothelial tumours. In this study the researchers analysed the oncological outcomes of patients with such histology in comparison to...

Bladder Pain Syndrome – An Evolution, 2nd Edition

Bladder pain syndrome remains the focus of much debate and discussion, and this will continue in the future. This book is the second edition of Interstitial Cystitis which was published three decades ago. Given that a lot has happened in...

Long-term risks of augmenting the bladder in spina bifida patients

Bladder augmentation is utilised to treat children with neuropathic bladders secondary to spina bifida that results in hostile urodynamics, renal deterioration and / or urinary incontinence. Whilst it is associated with an improved quality of life and low mortality, it...

Secondary bladder cancer following upper tract urothelial cancer

Upper tract urothelial carcinoma (UTUC) comprises <5% of all urothelial cancers. A certain proportion of patients with UTUC will develop secondary bladder urothelial cancer (BUC). This paper has retrospectively examined records obtained from several cancer USA population-based registries of more...

The importance of second-look transurethral resection for superficial bladder cancer

This was a prospective study of 100 consecutive patients with a newly diagnosed superficial bladder tumour who underwent a second look transurethral resection of bladder tumour (TURBT) two to six weeks post initial resection. This essentially included pTa multiple and...

BCG strain differences have an impact on clinical outcome in bladder cancer immunotherapy

Bacillus Calmette-Guérin (BCG) has been part of the treatment algorithm for non-muscle invasive bladder cancer (NMIBC) for a number of years. In this single centre, prospective, randomised trial, two of the most commonly available strains, BCG Connaught and BCG Tice,...

Repeat transurethral resection in non-muscle invasive bladder cancer

The authors felt this is a big problem because there is no standardised practice on re-resection following initial transurethral resection of bladder tumour (TURBT). Getting detrusor muscle in the first specimen is thought to be important. However muscle is not...